Long-Term Effects of Fish Oil on Insulin Resistance and Plasma Lipoproteins in NIDDM Patients With Hypertriglyceridemia

Aa, Rivellese; Maffettone, Ada; Iovine, C; L, Di Marino; Annuzzi, Giovanni; Mancini, Milena; Riccardi, Gabriele

doi:10.2337/diacare.19.11.1207

“…The trials included in the pooled analyses were small, with a median of 23 patients. Seventeen of the published papers were duplicate publications of six trials [22, 27, 33, 34, 36-38, 40, 42-46, 48, 51, 54, 55]; multiple papers for each trial are indicated by the following grouping of references: [22,38], [27,34,36,37], [40,54,55], [42,48,51], [43,46], [44,45]. There was sufficient information on only 12 of the 98 outcomes to allow data to be pooled, the results of which are shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…The trials reporting HLD-2 and HDL-3 were of 8 weeks duration or less. Three trials reported changes in HDL-TG among 80 non-hypertriacylglycerolaemic subjects [34,47,48]. n-3 PUFA non-significantly decreased HDL-TG by 0.01 mmol/l (95% CI −0.05 to 0.03; p=0.65) (ESM Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Four trials reported changes in LDL-TG among 106 nonhypertriacylglycerolaemic subjects [34,[47][48][49] (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

“…Four trials reported changes in LDL:HDL ratio among 116 subjects [25,46,48,52] involved in trials lasting longer than 8 weeks (Table 2). However, data from these trials could not be pooled.…”

Section: Resultsmentioning

confidence: 99%

“…Nine ratio markers reported by eight trials could not be pooled [25,32,34,43,[48][49][50]52] (Table 2). apoAI:apoAII was assessed in ten subjects indicating no change with n-3 PUFA [32].…”

Section: Very Low Density Lipoprotein Cholesterol and Subfractionsmentioning

confidence: 99%

See 3 more Smart Citations

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes

Hartweg

¹

,

Farmer

²

,

Perera

³

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis To determine the effects of marine-derived n-3 polyunsaturated fatty acids (PUFA) on established and emerging lipid and lipoprotein cardiovascular risk markers in patients with type 2 diabetes. Materials and methods We performed a systematic review and meta-analysis of randomised controlled trials comparing dietary or non-dietary intake of n-3 PUFA with placebo in patients with type 2 diabetes by searching databases from 1966 to December 2006. Changes in the following variables were recorded triacylglycerol; total cholesterol; HDL, LDL and VLDL and their subfractions; lipid ratios; apolipoproteins; and cholesterol particle sizes. Results There were 23 trials on non-dietary supplementation, involving 1,075 subjects with a mean treatment duration of 8.9 weeks, with sufficient data to permit pooling. Compared with placebo, n-3 PUFA had a statistically significant effect on four outcomes, reducing levels of (1) triacylglycerol (18 trials, 969 subjects) by 25% (mean 0.45 mmol/l; 95% CI −0.58 to −0.32; p<0.00001); (2) VLDL-cholesterol (7 trials, 238 subjects) by 36% (0.07 mmol/l; 95% CI −0.13 to 0.00; p=0.04); and (3) VLDL-triacylglycerol (6 trials, 178 subjects) by 39.7% (0.44 mmol/l; 95% CI −0.83 to −0.05; p= 0.03); while slightly increasing LDL (16 trials, 565 subjects) by 5.7% (0.11 mmol/l; 95% CI 0.00 to 0.22; p=0.05). There were no significant effects on total cholesterol, apolipoproteins, lipid subfractions or ratios. Conclusions/interpretation In addition to recognised triacylglycerol-lowering effects, n-3 PUFA supplementation decreases VLDL-cholesterol and VLDL-triacylglycerol, but may have an adverse effect on LDL-cholesterol. Larger and longer term clinical trials are required to conclusively establish the effect of n-3 PUFA on cardiovascular risk markers and outcomes in type 2 diabetic patients.

show abstract

N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?

Rubba

¹

2001

Eur. J. Lipid Sci. Technol.

View full text Add to dashboard Cite

IntroductionThe aim of this review is to cover the role of fatty acids (FA) in atherosclerosis and related disorders from the perspective of a clinician. It will therefore be almost exclusively focussed on human data. It will also necessarily reflect the experience gained at an institution located in the Mediterranean area, which devoted more than 30 years of nutritional research in relation to cardiovascular disease under the guidance of Mario Mancini. The Mediterranean area remains a southern relative of the industrialized countries of northern Europe. It has become integrated in the common cultural structure of the European Union unlike Magreb to the south and some countries such as Albania to the east [1-3]. FA and hyperlipidemiaThe relationship between dietary FA, serum cholesterol and coronary heart disease (CHD) has been first demonstrated by cross cultural comparisons [4,5]. The Seven Countries Study, started in the '60s, showed that cohorts of middle-aged men from South Europe (Italy, Greece, Yugoslavia) had a daily FA intake in the range of 24-27% of total energy (approximately 9% of saturated FA, 11% of monounsaturated FA, 3% of polyunsaturated FA). These figures were markedly less than those of population samples from northern Europe (such as Finland or the Netherlands), whose total fat intake was 34-38% (approximately 20% of saturated FA, 12% of monounsaturated FA, 3-5% of polyunsaturated FA). Circulating cholesterol and death rates from all causes or CHD were lower in cohorts from the Mediterranean area [4,5]. In a large study of several population samples representative of different Italian regions, a more frequent consumption of foods high in saturated FA was associated with higher plasma cholesterol [6]. retard early relapse in ulcerative colitis. Dig. Dis. Sci. 41(10) (1996) 2087-2094. [72] H.

show abstract

N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?

Rubba

¹

2001

Eur. J. Lipid Sci. Technol.

0

View full text Add to dashboard Cite

IntroductionThe aim of this review is to cover the role of fatty acids (FA) in atherosclerosis and related disorders from the perspective of a clinician. It will therefore be almost exclusively focussed on human data. It will also necessarily reflect the experience gained at an institution located in the Mediterranean area, which devoted more than 30 years of nutritional research in relation to cardiovascular disease under the guidance of Mario Mancini. The Mediterranean area remains a southern relative of the industrialized countries of northern Europe. It has become integrated in the common cultural structure of the European Union unlike Magreb to the south and some countries such as Albania to the east [1-3]. FA and hyperlipidemiaThe relationship between dietary FA, serum cholesterol and coronary heart disease (CHD) has been first demonstrated by cross cultural comparisons [4,5]. The Seven Countries Study, started in the '60s, showed that cohorts of middle-aged men from South Europe (Italy, Greece, Yugoslavia) had a daily FA intake in the range of 24-27% of total energy (approximately 9% of saturated FA, 11% of monounsaturated FA, 3% of polyunsaturated FA). These figures were markedly less than those of population samples from northern Europe (such as Finland or the Netherlands), whose total fat intake was 34-38% (approximately 20% of saturated FA, 12% of monounsaturated FA, 3-5% of polyunsaturated FA). Circulating cholesterol and death rates from all causes or CHD were lower in cohorts from the Mediterranean area [4,5]. In a large study of several population samples representative of different Italian regions, a more frequent consumption of foods high in saturated FA was associated with higher plasma cholesterol [6]. retard early relapse in ulcerative colitis. Dig. Dis. Sci. 41(10) (1996) 2087-2094. [72] H.

show abstract

Long-Term Effects of Fish Oil on Insulin Resistance and Plasma Lipoproteins in NIDDM Patients With Hypertriglyceridemia

Cited by 143 publications

References 0 publications

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes

N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?

N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?

Contact Info

Product

Resources

About